INTRODUCTION
Mycophenolate mofetil (MM) is a commonly used immunosuppressant for patients with autoimmune diseases and for those who have undergone organ transplantation. Anemia, leukopenia, mucositis and opportunistic infections are common side effects of MM. We report a case of mycophenolate associated pulmonary alveolar proteinosis (PAP) in a patient with Wegener's granulomatosis (WG). PAP is a disease characterized by defects in macrophage-mediated processing of surfactants, leading to accumulation of periodic acid Schiff (PAS)-positive lipoproteinaceous material within the alveolar spaces 1 .
CASE REPORT
A 67-year-old woman with a history of WG-associated interstitial lung disease (ILD) presented to the emergency room with worsening shortness of breath, a non-productive cough and subjective fevers. Her symptoms had progressed over a 6-month period from dyspnea on exertion to shortness of breath at rest. During this time, her dose of mycophenolate mofetil was gradually increased from 500 to 2,000 mg per day for presumed worsening of her ILD. She was also started on sildenafil for secondary pulmonary hypertension from underlying interstitial lung disease. Despite these changes to her medications, her symptoms worsened. Her supplemental oxygen requirement also increased from a fraction of inspired oxygen (FiO 2 ) of 28% to 50% over the 6-month period. However, her anti-neutrophil cytoplasmic antibody (ANCA) titers steadily decreased and were negative 3 months prior to her presentation at the emergency room.
She had been diagnosed with WG 3 years prior to admission. At that time, she presented with acute renal failure, a creatinine of 2.33 mg/dl and microscopic hematuria. A kidney biopsy revealed focal proliferative and sclerosing glomerulonephritis. She was also noted to have ILD at her initial presentation based on computed tomography (CT) of the lungs. Serum anti-neutrophil cytoplasmic antibody (ANCA) titers were 1:256 (normal, less than 1:20; significant titers, greater than 1:40-1:80). Symptoms did not improve on initial therapy with corticosteroids and cyclophosphamide. The patient was switched to a combination of MM and corticosteroids. She developed severe myopathy and hyperglycemia, and the corticosteroids were gradually tapered and stopped.
On examination, she was afebrile and in moderate respiratory distress. She was unable to speak in complete sentences. Auscultation of the chest revealed diffuse bilateral coarse breath sounds. The cardiac examination was normal. Examination of the extremities revealed clubbing and 1+ bilateral lower extremity edema. The remainder of the physical examination was unremarkable.
Initial laboratory findings are shown in Table 2) .
The chest radiograph showed diffuse bilateral reticulonodular interstitial opacities. High-resolution CT scan revealed subpleural cysts/honeycombing with evidence of traction bronchiectasis ( Fig. 1 ). In addition, there were diffuse ground-glass and alveolar opacities. These opacities were new since the patient's prior chest CT 3 years ago, which revealed only subpleural cysts/honeycombing (Fig. 2) . While not typical, honeycombing and interstitial fibrosis have been reported in patients with WG 2 . The presence of new ground-glass and alveolar opacities, as well as the subjective fevers, in an immunocompromised host raised suspicion for superimposed infection. Bronchoscopy with a bronchoalveolar lavage (BAL) was performed. The BAL returns were opaque and milky. Cytopathology revealed abundant inspissated lipoproteinaceous material. The material was periodic acid Shiff (PAS) positive, which was evidence of the glycosylated phospholipids present in the surfactant (Fig. 3) . No inflammatory cells were noted in the BAL. Stains for pneumocystis, fungi and acid-fast bacilli were negative, and no viral changes were identified. BAL cultures for bacteria, fungi, acid-fast bacilli and viruses were negative. Because of worsening respiratory status, presence of ground-glass opacities on the high-resolution CT, the milky return on the bronchoalveolar lavage and the PAS-positive extracellular material on BAL, the patient was diagnosed with pulmonary alveolar proteinosis. This was thought to be secondary to MM as her symptoms developed after starting the drug and worsened with dose escalation.
An attempt to discontinue MM was unsuccessful. The patient's renal function worsened with reduction in mycophenolate from 2 g to 1.5 g. Because of a history of previous intolerance to cyclophosphamide and prednisone, a change in the immunosuppressant was not an option. Instead, the patient was started on granulocyte macrophage colony-stimulating factor (GM-CSF). Her symptoms improved in the ensuing 4 months. However, due to worsening renal function, GM-CSF therapy had to be discontinued. Subsequently, she became more dyspneic and hypoxemic, requiring increased oxygen supplementation. A whole lung lavage resulted in improvement 
DISCUSSION
Pulmonary alveolar proteinosis (PAP) is a non-inflammatory lung disorder, with an annual incidence of 0.36 cases per million. It is characterized by the accumulation of lipoproteinaceous material due to impairment in macrophage clearance of the alveolar surfactant. These patients typically present with progressive dyspnea, cough, low-grade fevers and fatigue. Laboratory testing often reveals an elevated LDH, as was seen in our patient. Radiographic findings include bilateral alveolar and interstitial disease on chest x-ray and a crazy paving pattern on high-resolution CT. Crazy paving is the combination of ground-glass opacification and septal thickening. BAL characteristically reveals milky-appearing fluid. Microscopic examination of the fluid may show large foamy alveolar macrophages as well as extracellular debris derived from surfactant. This debris, especially if present in small amounts, may not be seen on standard staining such as May-Grunwald-Giemsa and Papanicolaou staining, but is seen well with PAS staining. While BAL findings are usually sufficient, the gold standard for diagnosis is open lung biopsy 1, 3 . PAP may be classified as congenital, acquired and secondary. Congenital PAP is thought to result from mutations in surfactant protein B and C or a mutation in the beta-C chain of the GM-CSF receptor on pulmonary macrophages. Acquired PAP is usually a result of GM-CSF antibodies causing macrophage dysfunction.
Secondary PAP is due to qualitative or quantitative macrophage dysfunction as a result of environmental exposures (i.e., silica, cement dust, cellulose fibers, aluminum dust and titanium dioxide 1 ), autoimmune diseases or immunosuppression. The latter may be from underlying hematological malignancies or immunosuppressive medications 1, 3 . Macrophage dysfunction in secondary PAP is a result of the underlying immunodeficient state and not anti-GM-CSF antibodies.
Malignancies, especially hematological malignancies, are associated with both quantitative and qualitative macrophage impairment [4] [5] [6] [7] . Chronic myeloid leukemia is most commonly associated with PAP 8 . However, the role of malignancy is complicated by the fact that the treatment for malignancies often involves the use of immunosuppressive medications.
Immunosuppressive medications reported to be associated with PAP include corticosteroids, leflunomide, sirolimus, tacrolimus, cyclosporine, azathioprine and busulfan [4] [5] [6] [7] [9] [10] [11] [12] . To our knowledge, this case is the first to report an association of mycophenolate mofetil with PAP.
Mycophenolate interrupts de novo purine synthesis by inhibiting inosine monophosphate dehydrogenase. Because lymphocytes do not have a salvage pathway by which to recycle purine nucleotides, they depend on the de novo pathway for the supply of these nucleotides. Thus, inhibition of the de novo pathway results in depletion of these nucleotides, impairing DNA synthesis. This results in impairment of cell-mediated immunity, which may lead to macrophage dysfunction. Another consequence of depletion of guanosine nucleotides is reduced mannosylation of membrane glycoproteins (guanosine nucleotides form complexes with mannose in the mannosylation process). This results in altered adhesion molecules on the surface of monocytes, preventing them from interacting with and migrating across the alveolar endothelium. This may lead to a decrease in the alveolar macrophage pool and reduced surfactant clearance 13, 14 . PAP has been associated with autoimmune disorders such as rheumatoid arthritis, IgA nephropathy, multiple sclerosis and dermatomyositis, as well as in a patient with smooth muscle antibodies 3, 11, 15, 16 . There is one prior case report of WGassociated PAP 12 . Most of these patients are also on immunosuppressive medications; the reported patient with WG was on cyclophosphamide and prednisone at the time of diagnosis of PAP. Thus, it is difficult to assess the contribution of autoimmune disease in the development of PAP. It is feasible that anti-GM-CSF antibodies may occur with WG-associated hypergammaglobulinemia. However, as in the previous reported case, ANCA titers in our patient were negative at presentation, indicating good control of the underlying WG. Therefore, mycophenolate mofetil is more likely responsible for the development of PAP.
Acquired PAP resolves spontaneously in 10% to 30% of patients 1, 3 . The remaining patients have either stable symptoms or progressive worsening. The standard of care for treatment is whole lung lavage, which removes the lipoproteinaceous material in the alveoli, allowing for improved gas exchange. Whole lung lavage improved symptoms in 84% of reported cases 3 . The median duration of response is about 15 months, and whole lung lavage may be repeated as necessary 1 . Other options include therapy with subcutaneous GM-CSF, which, at a dose of 5-9 µg/kg/day, results in improved symptoms in about 50% of patients 3 . GM-CSF works by stimulating alveolar macrophages to clear the surfactant 3 . Treatment of secondary PAP consists of treating the underlying disease or withdrawing immunosuppresion if possible 8 . If unsuccessful, whole lung lavage should be performed. GM-CSF has not been studied in secondary PAP, and therapy with GM-CSF in patients with autoimmune disease should be undertaken with caution so as not to worsen the underlying medical condition.
CONCLUSION
We present evidence that mycophenolate mofetil, like most other immunosuppressants, may be associated with the development of PAP. Presentation of PAP can be subtle and often confused with worsening of underlying lung disease. This case demonstrates the importance of including PAP in the differential diagnosis in patients with WG who have worsening of their lung disease while on mycophenolate. Accurate diagnosis of this condition can allow for appropriate treatment, including withdrawal of immunosuppression, GM-CSF therapy and whole lung lavage. The latter is indicated for patients with worsening symptoms despite reduction in immunosuppressive therapy, especially those with significant arterial hypoxemia or significant symptoms, either at rest or with exertion 17 .
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